CA2197139A1 - A drug for the treatment of cancer - Google Patents

A drug for the treatment of cancer

Info

Publication number
CA2197139A1
CA2197139A1 CA002197139A CA2197139A CA2197139A1 CA 2197139 A1 CA2197139 A1 CA 2197139A1 CA 002197139 A CA002197139 A CA 002197139A CA 2197139 A CA2197139 A CA 2197139A CA 2197139 A1 CA2197139 A1 CA 2197139A1
Authority
CA
Canada
Prior art keywords
treatment
bombesin
vip
somatostatin
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002197139A
Other languages
French (fr)
Other versions
CA2197139C (en
Inventor
Rama Mukherjee
Manu Jaggi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Immunology
Original Assignee
National Institute of Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/727,679 external-priority patent/US6156725A/en
Application filed by National Institute of Immunology filed Critical National Institute of Immunology
Publication of CA2197139A1 publication Critical patent/CA2197139A1/en
Application granted granted Critical
Publication of CA2197139C publication Critical patent/CA2197139C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition useful for killing or inhibiting multiplication of cancer cells. It is expected that the pharmaceutical composition will be useful in preventing, inhibiting, or modulating the hypersecretion of VIP, somatostatin, bombesin, Substance P, or a combination of VIP, somatostatin, bombesin, or Substance P.
The composition may suitably comprise, consist of, or consist essentially of a therapeutically effective combination of peptide analogs of somatostatin, VIP, bombesin and Substance P. Also provided is a method of treatment for humans or other animals suffering from cancer, the method comprising administering a therapeutically effective dose of the pharmaceutical composition so as to kill or inhibit the multiplication of cancer cells. The method of treatment may be particularly useful in the treatment of cancers of the colon and rectum. Also provided is a method of treatment for humans or animals having hypersecretion or modulation of VIP, somatostatin, bombesin, Substance P, or a combination of VIP, somatostatin, bombesin, or Substance P.
CA002197139A 1996-08-16 1997-02-10 A drug for the treatment of cancer Expired - Fee Related CA2197139C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1822DE1996 1996-08-16
IN1822/DEL/96 1996-08-16
US08/727,679 US6156725A (en) 1996-08-16 1996-10-08 Drug for the treatment of cancer
US08/727,679 1996-10-08

Publications (2)

Publication Number Publication Date
CA2197139A1 true CA2197139A1 (en) 1998-02-17
CA2197139C CA2197139C (en) 2003-07-08

Family

ID=26324708

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002197139A Expired - Fee Related CA2197139C (en) 1996-08-16 1997-02-10 A drug for the treatment of cancer

Country Status (3)

Country Link
JP (1) JPH1067676A (en)
AU (1) AU707158B2 (en)
CA (1) CA2197139C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263125A3 (en) * 2011-02-02 2018-03-14 Emory University Antagonism of the vip signaling pathway

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022507688A (en) * 2018-11-15 2022-01-18 エモリー ユニバーシティー Compositions and Uses of Vasoactive Intestinal Peptide (VIP) Antagonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263125A3 (en) * 2011-02-02 2018-03-14 Emory University Antagonism of the vip signaling pathway
US11464855B2 (en) 2011-02-02 2022-10-11 Emory University Antagonism of the VIP signaling pathway

Also Published As

Publication number Publication date
CA2197139C (en) 2003-07-08
AU707158B2 (en) 1999-07-01
JPH1067676A (en) 1998-03-10
AU1014997A (en) 1998-02-26

Similar Documents

Publication Publication Date Title
CA2214097A1 (en) Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
PL329802A1 (en) Derivatives of androstene
NZ503233A (en) Synergistic analgesic combination of opioid analgesic and COX-2 inhibitor
AU7031500A (en) Therapeutic quinazoline compounds
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
NO20014046L (en) Gabapentin derivatives for the prevention and treatment of visceral pain
AU4830097A (en) Use of an extract of Cimicifuga
EP0835662A3 (en) A drug for the treatment of cancer
MX9504023A (en) Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid.
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
SI0800399T1 (en) Combined therapeutical treatment of hyperproliferative diseases
GB9907571D0 (en) Compounds
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
BG102667A (en) Diosgenine-containing composition
FR2500303B1 (en)
CA2197139A1 (en) A drug for the treatment of cancer
EP0821969A3 (en) Medicinal Composition comprising TCF-II
TR199801184T2 (en) New compounds with analgesic action.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
MD798G2 (en) Method of the mamma cancer treatment
UA41326C2 (en) Pharmaceutical composition for prevention or treatment of viral diseases, means for prevention or treatment of viral diseases
AU5434899A (en) Cancer treatment
WO1998046193A3 (en) Synergistic method for treating a neoplasm
RU97110400A (en) METHOD FOR PREVENTION AND TREATMENT OF PATIENTS SUFFERING WITH ESTROGEN- AND ANDROGEN-DEPENDENT TUMORS

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed